EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer EMA Recommends Extension of Therapeutic Indications for Asciminib MOST POPULAR ctDNA Sequencing Reliably Detects KIT/PDGFRA Mutations and Correlates with Outcomes in... May 23, 2023 Transforming Cancer Clinical Trials for Better, Faster Results April 14, 2023 A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... August 5, 2025 Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 Load more HOT NEWS Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma NICE doesn’t recommend olaparib for patients with certain prostate cancers Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses
